Piramal Group

Valued at US$ 10 Billion, Piramal Group is a global business conglomerate with diverse interests in Pharma, Financial Services, Information Management, Real Estate and Glass Packaging. The Group has offices in over 30 countries and a global brand presence in more than 100 markets.

Under the aegis of Mr. Ajay Piramal, the Chairman, Piramal Group is a torchbearer of trusteeship and responsible business ethos. Based on the philosophy of ‘Doing Well and Doing Good’, the Group continues to create long-term value for its stakeholders and the community at large.

Driven by its core values, Piramal Group steadfastly pursues inclusive growth, while adhering to ethical and values-driven practices.

Know More

Piramal Enterprises Limited (PEL), the flagship company of the Piramal Group, is one of India’s large diversified companies with presence in Pharma, Financial Services and Healthcare Information Management. The company generates ~46% of its revenues from international markets. Driven by both organic as well as inorganic strategy, PEL has steered dynamic business growth over the three decades of its existence.

Know More

Piramal Capital & Housing Finance Limited (PCHFL), wholly owned subsidiary of Piramal Enterprises Limited (the flagship company of Piramal Group), is registered as a housing finance company with National Housing Bank (NHB) and is engaged in various financial services businesses. It provides both wholesale and retail funding opportunities across sectors. In real estate, the platform provides housing finance and other financing solutions across the entire capital stack ranging from early stage private equity, structured debt, senior secured debt, construction finance and flexi lease rental discounting. The wholesale business in non-real estate sector includes separate verticals- Corporate Finance (CFG) and Emerging Corporate Lending (ECL). CFG provides customized funding solutions to companies across sectors such as infrastructure, renewable energy, roads, industrials, auto components etc. while ECL focuses on lending towards Small and Medium Enterprises (SMEs). PCHFL through its group companies provides customized strategies for institutional and retail investors such as Mumbai Redevelopment Fund and Apartment Fund (through Piramal Fund Management) and strategic partnerships with leading global pension funds such as CPPIB, APG and Ivanhoe Cambridge.

Know More

India Resurgence Fund (IndiaRF), an equal joint venture between Piramal Enterprises Limited and Bain Capital Credit, invests capital in the form of both debt and equity, in distress to control situations in the Indian market, through its flexible strategic model. IndiaRF looks to invest in businesses that require balance sheet restructuring, and engage with companies that have fundamentally strong growth prospects linked to the infrastructure and consumption needs of India and that are competitive on cost and quality in the export markets.

India Resurgence Fund (IndiaRF), an equal joint venture between Piramal Enterprises Limited and Bain Capital Credit, invests capital in the form of both debt and equity, in distress to control situations in the Indian market, through its flexible strategic model. IndiaRF looks to invest in businesses that require balance sheet restructuring, and engage with companies that have fundamentally strong growth prospects linked to the infrastructure and consumption needs of India and that are competitive on cost and quality in the export markets.

Know More

IndUS Growth Partners, an affiliate of the Piramal Group, is a global strategic investor with committed access to over US$ 2 Billion in liquid capital.

Leveraging our global presence and expertise, IndUS targets long-term growth investments while providing operational leverage, support to existing management, and local access to the India growth story.

Based on its values-focused management perspective, the companies that IndUs Growth Partners has invested in, have accelerated profits at a CAGR of 36% over the last 25 years.

Know More

Piramal Pharma Solutions is the Contract Development and Manufacturing Organisation (CDMO) business division of Piramal Enterprises Limited, with operations in North America, Europe and Asia. A global leader in integrated solutions, it offers a comprehensive range of services across the drug lifecycle from drug discovery services and development to commercial manufacturing of drug substances and drug products. Leveraging its capabilities as an integrated service provider and experience with various cutting-edge technologies, enables Piramal Pharma Solutions effectively serves innovator and generic companies worldwide. With accreditations from regulatory bodies in the US, Europe & Japan, its development centres and manufacturing sites across the globe, have a pool of over 450 scientists, including 155 Ph.Ds. committed to research and development programs.

Piramal Pharma Solutions is committed towards translating your high potency discovery to commercial reality. A ‘Customer Centric’ organization, Piramal Pharma Solutions has the “Pulse of the Customer” at the heart of its mission.

Know More

Piramal Critical Care (PCC), a business division of Piramal Enterprises Limited, is the third largest producer of Inhaled Anesthetics and a global player in hospital generics. Motivated by its vision to deliver critical care solutions for patients and healthcare providers across the globe, PCC is committed to enabling sustainable and profitable growth for all its stakeholders.

PCC maintains a wide presence across the USA, Europe and more than 100 countries across the globe. Its rich product portfolio includes Inhalation Anesthetics such as Sevoflurane, Isoflurane and Halothane as well as Intrathecal Baclofen therapy, for spasticity management. PCC has wholly owned, state-of-the-art manufacturing facilities in the US and India that have successfully cleared periodical inspections by the US FDA, UK MHRA and other regulators.

Its core strength lies in a highly qualified global workforce of more than 400 employees across 16 countries. PCC is focused on further expanding its global footprint through new product additions in the critical care space. Committed to corporate social responsibility alongside Piramal Group, PCC collaborates with various partner organizations and proudly takes an active role in providing hope and resources to those in need, as well as caring for the environment.

Know More

The Consumer Products Division, a division of Piramal Enterprises Limited, caters to the Indian self-care market, and is one of the fastest growing businesses of the company.

Piramal Enterprises Limited made its foray into the Over-the-Counter (OTC) market after acquiring Saridon from Roche and Lacto Calamine from Duphar in the early 1990s.

The business has a well-positioned product portfolio with a purpose to improve people’s lives by offering products that address their routine-disruptors.

Currently ranked 5th in the OTC segment, it has a reach of 7 Crore consumers a month. The Consumer Products Division has a diverse product range of 21 brands across categories such as Skin Care, Vitamins & Nutrition, Antacids, Analgesics, Gastro-intestinal and Baby-Care. Most of its brands are either No. 1 or No. 2 in their respective markets and product category. In addition, six brands feature amongst the Top 100 OTC brands.

Know More

The Phytomedicines business division of Piramal Enterprises Limited, is involved in the development of novel healthcare solutions from natural sources and its commercialization in global markets. The division aims to leverage India’s biodiversity and substantial knowledge in traditional medicinal systems such as Ayurveda, as a source for new medications.

Currently, the Phytomedicines business division has ~32 phytopharmaceuticals in its portfolio that includes polyherbals and 6 patented products to help manage various lifestyle ailments.

Its diverse range of products include cough-cold, women-care range, lifestyle disorder products like stress relievers, sleep disorders, piles, skin care-topicals, immunity enhancer, liver disorder and many others along with its premium, clinically validated, globally patented product ‘Tinefcon’ – India’s first oral treatment for psoriasis

Know More

Founded in 2012, Piramal Realty Ltd. is the real estate development arm of the Piramal Group. Piramal Realty aims to be one of India’s most admired real estate companies, by setting new standards for architectural design, customer-centricity, quality and safety in the industry.

It has over 15 Mn sq. ft. of commercial, residential and mixed-use developments in prime areas of Mumbai. In 2015, leading global investors, Warburg Pincus and Goldman Sachs invested US$ 434 Mn in the company, making it one of the largest FDI Investments in the Indian real estate industry.

Know More

Piramal Foundation, the philanthropic arm of the Piramal Group, is a Section 8 company that develops innovative solutions to resolve issues that are critical roadblocks towards unlocking India’s economic potential.

The Foundation believes that bringing impact at scale across diverse geographies and communities can be achieved through partnerships with governments and like-minded organisations. Therefore, all of its projects are in conjunction with state and central governments, like-minded philanthropists, corporates, donors, NGOs and social delivery organisations.

In line with the Millennium Development Goals, Piramal Foundation is committed towards improving primary healthcare and nutrition, primary education and enabling access to safe drinking water.

Each social initiative nurtured by Piramal Foundation, addresses one of the three focus areas that include –

  • Primary Health & Nutrition – Piramal Swasthya
  • Education – Piramal Foundation for Education Leadership
  • Safe Drinking Water – Piramal Sarvajal

The Foundation’s initiatives are a reflection of the Group’s core values and corporate philosophy of ‘Doing Well and Doing Good’.

Know More